Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Euphrasia Eye Drops for CNLDO in Preterm Infants
NCT04122300Phase 3Completed
- Sponsor
- University of Bern
- Start
- May 2011
- Primary completion
- Dec 2016
- Modality
- Herbal Medicine, Dietary Supplement, Homeopathic remedy
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in congenital nasolacrimal duct obstruction (CNLDO) comparing Euphrasia arm with Placebo arm (2 arms). Primary endpoint: Number of patients with treatment success at 96 hours. Started May 2011; status: completed.
02
Drugs
euphrasia
03
Conditions
congenital nasolacrimal duct obstruction (CNLDO)
Beyond the preview
Go deeper on NCT04122300.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04122300.